Cagrilintide (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Cagrilintide (research code AM833) is a long-acting acylated analogue of the pancreatic hormone amylin, studied in the metabolic literature for once-weekly satiety and appetite-regulation modelling. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published trials, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 2.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that fill, every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 1 mg of material, so each milligram corresponds to exactly 10 units — keeping the arithmetic clean across every titration step and letting the whole weekly range stay within a single insulin syringe.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation arms used in the Phase 2 dose-finding program, where weekly amounts were stepped up roughly every two weeks to manage gastrointestinal tolerability before settling at a maintenance level.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 2.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Accelerated) Titration Schedule

The accelerated schedule reaches the 4.5 mg ceiling sooner by halving the time spent at each interim step. It escalates faster but tends to provoke more pronounced gastrointestinal effects during the ramp, so it is the less tolerable of the two published-style patterns.

Supplies Needed

• Cagrilintide vials (20 mg): ~1 vial for an 8-week titration run; ~2 vials for a 12-week run; ~3 vials for a full 16-week run to maintenance.
• Insulin syringes (U-100, 1 mL): one fresh syringe per weekly draw — 8 for an 8-week schedule, 16 for a 16-week schedule. Every step in the range stays under 50 units, so no larger barrel is needed.
• Bacteriostatic water (10 mL): one bottle covers ~5 vials at 2 mL each.
• Alcohol swabs: a single 100-count box comfortably covers a 16-week schedule.

Protocol Overview

• Research goal: model appetite suppression and satiety signalling through central amylin-receptor activation.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 0.6–4.5 mg weekly, escalated in steps to a 4.5 mg maintenance level.
• Fill: 20 mg lyophilized, reconstituted to 10 mg/mL with 2 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 0.6 mg step and hold each interim level for about two weeks before escalating.
• Keep administration on a fixed weekly cadence and the same day where possible for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• The 4.5 mg maintenance level carries the bulk of the published efficacy signal.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light and moisture, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 30 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Because the full weekly range fits in one U-100 syringe, no dose needs to be split across barrels.
• Document each draw — date, volume, remaining material — for reproducibility.

How Cagrilintide Works

Cagrilintide is a synthetic, long-acting analogue of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. It engages central amylin receptors to promote satiety, slow gastric emptying and reduce food intake, complementing the incretin pathways targeted by GLP-1 agonists. A lipid (fatty-acid) modification extends its half-life to roughly 160–195 hours, which is what supports once-weekly dosing in trials and distinguishes it from native amylin and shorter-acting analogues. In the comparative literature it is frequently paired with semaglutide (the CagriSema combination) to study additive weight effects.

Reported Benefits & Side Effects

Benefits observed in trials

• Roughly 10.8% average body-weight reduction at the 4.5 mg dose over 26 weeks in the Phase 2 dose-finding study, versus about 3% on placebo.
• Clear dose-dependent response, with the 2.4–4.5 mg band outperforming the lower 0.3–1.2 mg steps.
• In combination with semaglutide (CagriSema), Phase 3 REDEFINE trials reported approximately 20% weight loss at 68 weeks.
• Reductions in appetite and food intake consistent with its satiety mechanism.

Side effects reported

• Predominantly gastrointestinal — nausea, vomiting, diarrhoea and constipation — generally mild-to-moderate and transient.
• Occasional mild redness or irritation at the injection site.
• Gradual titration markedly reduces the frequency and severity of these effects.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition in the published study designs.
• Combined resistance and aerobic activity to preserve lean mass during weight reduction.
• Adequate sleep, stress management and hydration as standard trial controls.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• The full weekly range fits a single injection, so volume-splitting is not needed at this concentration.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols